PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions
PTCT Stock Forecast
PTC Therapeutics stock forecast is as follows: an average price target of $44.33 (represents a 30.42% upside from PTCT’s last price of $33.99) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
PTCT Price Target
The average price target for PTC Therapeutics (PTCT) is $44.33 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $32.00. This represents a potential 30.42% upside from PTCT's last price of $33.99.
PTCT Analyst Ratings
According to 10 Wall Street analysts, PTC Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for PTCT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (30.00%), 5 'Hold' (50.00%), 2 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
PTC Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Colin Bristow | UBS | $47.00 | $34.99 | 34.32% | 38.28% |
| Jul 12, 2024 | Jeffrey Hung | Morgan Stanley | $32.00 | $33.20 | -3.61% | -5.85% |
| May 20, 2024 | Paul Choi | Goldman Sachs | $32.00 | $40.12 | -20.24% | -5.85% |
| May 20, 2024 | Kelly Shi | Jefferies | $46.00 | $39.81 | 15.55% | 35.33% |
| Apr 26, 2024 | Jeffrey Hung | Morgan Stanley | $30.00 | $28.57 | 5.01% | -11.74% |
| Dec 14, 2022 | - | Goldman Sachs | $35.00 | $38.94 | -10.11% | 2.97% |
| Jun 23, 2022 | Brian Abrahams | RBC Capital | $46.00 | $38.29 | 20.14% | 35.33% |
| Apr 05, 2022 | Kristen Kluska | Cantor Fitzgerald | $63.00 | $43.64 | 44.36% | 85.35% |
| Aug 31, 2021 | Colin Bristow | UBS | $45.00 | $43.65 | 3.09% | 32.39% |
The latest PTC Therapeutics stock forecast, released on Aug 26, 2024 by Colin Bristow from UBS, set a price target of $47.00, which represents a 34.32% increase from the stock price at the time of the forecast ($34.99), and a 38.28% increase from PTCT last price ($33.99).
PTC Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $47.00 | $39.50 | $37.40 |
| Last Closing Price | $33.99 | $33.99 | $33.99 |
| Upside/Downside | 38.28% | 16.21% | 10.03% |
In the current month, the average price target of PTC Therapeutics stock is $47.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 38.28% increase as opposed to PTC Therapeutics's last price of $33.99. This month's average price target is up 18.99% compared to last quarter, and up 25.67% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 05, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 26, 2024 | UBS | - | Buy | Upgrade |
| Aug 09, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 09, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 01, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 20, 2024 | Citigroup | Sell | Sell | Hold |
| May 20, 2024 | Citigroup | Sell | Sell | Hold |
| May 20, 2024 | Goldman Sachs | Sell | Sell | Hold |
PTC Therapeutics's last stock rating was published by Morgan Stanley on Sep 05, 2024. The company gave PTCT a "Equal-Weight" rating, the same as its previous rate.
PTC Therapeutics Financial Forecast
PTC Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $307.06M | $196.58M | $213.81M | $220.38M | $167.41M | $217.13M | - | $148.74M | $165.23M | $138.74M | $116.68M | $117.94M | $118.86M | $118.40M | $75.24M | $68.26M | $96.46M | $71.42M |
| Avg Forecast | $325.73M | $315.16M | $286.54M | $261.15M | $205.71M | $169.28M | $157.41M | $142.88M | $167.02M | $172.01M | $183.28M | $165.49M | $314.96M | $210.23M | $206.99M | $200.52M | $188.38M | $178.52M | $162.12M | $146.91M | $150.83M | $120.44M | $110.13M | $98.82M | $113.35M | $112.21M | $82.04M | $80.02M | $95.19M | $73.03M |
| High Forecast | $357.57M | $345.96M | $314.54M | $286.67M | $225.81M | $185.83M | $172.80M | $156.85M | $183.34M | $182.02M | $201.20M | $181.66M | $320.66M | $230.78M | $227.22M | $220.11M | $206.80M | $195.96M | $162.12M | $172.79M | $177.40M | $141.66M | $129.53M | $116.23M | $133.32M | $131.98M | $96.50M | $94.12M | $111.96M | $85.89M |
| Low Forecast | $293.39M | $283.86M | $258.09M | $235.21M | $185.28M | $152.47M | $141.78M | $128.70M | $150.43M | $157.25M | $165.08M | $149.05M | $311.87M | $189.36M | $186.44M | $180.61M | $169.68M | $160.79M | $162.12M | $124.75M | $128.08M | $102.28M | $93.52M | $83.91M | $96.25M | $95.29M | $69.67M | $67.95M | $80.83M | $62.01M |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.94% | 1.03% | 1.10% | 0.89% | 1.22% | - | 1.01% | 1.10% | 1.15% | 1.06% | 1.19% | 1.05% | 1.06% | 0.92% | 0.85% | 1.01% | 0.98% |
PTC Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.49M, with a low forecast of $149.05M, and a high forecast of $181.66M. PTCT's average Quarter revenue forecast represents a -46.11% decrease compared to the company's last Quarter revenue of $307.06M (Dec 23).
PTC Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-334.83M | $-118.16M | $-209.54M | $-65.84M | $-89.75M | $-77.15M | - | $-83.76M | $-97.30M | $-95.11M | $-80.34M | $-95.44M | $-25.03M | $-14.55M | $-124.54M | $-97.59M | $-57.76M | $-52.20M |
| Avg Forecast | $-152.06M | $-147.13M | $-133.77M | $-121.91M | $-96.03M | $-79.03M | $-73.49M | $-66.70M | $-77.97M | $-80.30M | $-85.56M | $-71.60M | $-147.03M | $-98.14M | $-96.63M | $-65.10M | $-87.94M | $-76.53M | $-75.68M | $-59.18M | $-74.16M | $-69.58M | $-87.32M | $-75.22M | $-21.30M | $-198.63M | $-87.56M | $-62.37M | $-44.44M | $-31.59M |
| High Forecast | $-136.96M | $-132.52M | $-120.48M | $-109.81M | $-86.50M | $-71.18M | $-66.19M | $-60.08M | $-70.23M | $-73.41M | $-77.07M | $-57.28M | $-145.59M | $-88.40M | $-87.04M | $-52.08M | $-79.21M | $-61.23M | $-75.68M | $-47.34M | $-59.33M | $-55.66M | $-69.86M | $-60.17M | $-17.04M | $-158.91M | $-70.05M | $-49.89M | $-37.74M | $-25.27M |
| Low Forecast | $-166.92M | $-161.51M | $-146.84M | $-133.83M | $-105.42M | $-86.75M | $-80.67M | $-73.22M | $-85.59M | $-84.97M | $-93.92M | $-85.93M | $-149.69M | $-107.74M | $-106.07M | $-78.11M | $-96.54M | $-91.84M | $-75.68M | $-71.01M | $-88.99M | $-83.49M | $-104.79M | $-90.26M | $-25.56M | $-238.36M | $-105.08M | $-74.84M | $-52.27M | $-37.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.28% | 1.20% | 2.17% | 1.01% | 1.02% | 1.01% | - | 1.42% | 1.31% | 1.37% | 0.92% | 1.27% | 1.18% | 0.07% | 1.42% | 1.56% | 1.30% | 1.65% |
undefined analysts predict PTCT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PTC Therapeutics's previous annual EBITDA (undefined) of $NaN.
PTC Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-155.79M | $-132.97M | $-198.88M | $-138.96M | $-170.89M | $-109.31M | - | $-126.73M | $-143.26M | $-133.62M | $-118.37M | $-128.64M | $-74.35M | $-69.69M | $-181.43M | $-112.69M | $-77.68M | $-60.00M |
| Avg Forecast | $-16.78M | $-21.54M | $-31.39M | $-38.85M | $-30.95M | $-63.68M | $-79.60M | $-88.23M | $-104.05M | $-115.93M | $-85.92M | $-125.92M | $-10.60M | $-81.71M | $-124.40M | $-114.47M | $-121.78M | $-107.53M | $-104.66M | $-104.07M | $-109.20M | $-97.75M | $-128.66M | $-101.38M | $-63.28M | $-951.30M | $-127.56M | $-72.02M | $-33.83M | $-36.31M |
| High Forecast | $-14.61M | $-18.76M | $-27.34M | $-33.83M | $-26.95M | $-55.46M | $-69.33M | $-76.84M | $-90.62M | $-68.95M | $-74.83M | $-100.74M | $40.22M | $-71.16M | $-108.34M | $-91.58M | $-106.06M | $-86.02M | $-104.66M | $-83.25M | $-87.36M | $-78.20M | $-102.93M | $-81.10M | $-50.62M | $-761.04M | $-102.05M | $-57.61M | $-27.20M | $-29.05M |
| Low Forecast | $-18.91M | $-24.28M | $-35.38M | $-43.78M | $-34.88M | $-71.77M | $-89.72M | $-99.44M | $-117.27M | $-158.37M | $-96.84M | $-151.10M | $-32.18M | $-92.09M | $-140.20M | $-137.37M | $-137.26M | $-129.03M | $-104.66M | $-124.88M | $-131.04M | $-117.30M | $-154.40M | $-121.66M | $-75.94M | $-1.14B | $-153.07M | $-86.42M | $-41.58M | $-43.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 14.69% | 1.63% | 1.60% | 1.21% | 1.40% | 1.02% | - | 1.22% | 1.31% | 1.37% | 0.92% | 1.27% | 1.18% | 0.07% | 1.42% | 1.56% | 2.30% | 1.65% |
PTC Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PTC Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $76.29M | $80.89M | $88.45M | $86.91M | $92.72M | $80.12M | - | $73.27M | $86.55M | $69.25M | $68.88M | $61.09M | $75.46M | $57.84M | $53.66M | $66.16M | $71.47M | $56.31M |
| Avg Forecast | $172.99M | $167.37M | $152.17M | $138.69M | $109.25M | $89.90M | $83.60M | $75.88M | $88.70M | $91.35M | $97.34M | $72.81M | $167.26M | $111.65M | $109.93M | $66.19M | $100.04M | $55.73M | $86.10M | $60.17M | $65.97M | $50.66M | $74.87M | $48.15M | $64.22M | $59.59M | $37.73M | $42.28M | $50.55M | $34.08M |
| High Forecast | $189.89M | $183.73M | $167.05M | $152.24M | $119.92M | $98.69M | $91.77M | $83.30M | $97.37M | $96.67M | $106.85M | $87.37M | $170.29M | $122.56M | $120.67M | $79.42M | $109.82M | $66.87M | $86.10M | $72.20M | $79.16M | $60.79M | $89.84M | $57.78M | $77.06M | $70.09M | $45.27M | $50.74M | $59.46M | $40.90M |
| Low Forecast | $155.81M | $150.75M | $137.06M | $124.92M | $98.40M | $80.97M | $75.30M | $68.35M | $79.89M | $83.51M | $87.67M | $58.24M | $165.62M | $100.56M | $99.01M | $52.95M | $90.11M | $44.58M | $86.10M | $48.14M | $52.77M | $40.53M | $59.89M | $38.52M | $51.37M | $50.60M | $30.18M | $33.83M | $42.93M | $27.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.46% | 0.72% | 0.80% | 1.31% | 0.93% | 1.44% | - | 1.22% | 1.31% | 1.37% | 0.92% | 1.27% | 1.18% | 0.97% | 1.42% | 1.56% | 1.41% | 1.65% |
PTC Therapeutics's average Quarter SG&A projection for Mar 24 is $72.81M, based on 4 Wall Street analysts, with a range of $58.24M to $87.37M. The forecast indicates a -4.57% fall compared to PTCT last annual SG&A of $76.29M (Dec 23).
PTC Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-1.76 | $-0.00 | $-1.88 | $-2.35 | $-1.53 | - | $-1.78 | $-2.03 | $-1.89 | $-1.68 | $-1.83 | $-1.10 | $-1.03 | $-2.78 | $-1.81 | $-1.37 | $-1.06 |
| Avg Forecast | $-0.22 | $-0.28 | $-0.41 | $-0.51 | $-0.40 | $-0.83 | $-1.04 | $-1.15 | $-1.36 | $-1.51 | $-1.12 | $-1.27 | $-0.14 | $-1.06 | $-1.62 | $-1.53 | $-1.59 | $-1.28 | $-1.37 | $-1.51 | $-1.68 | $-1.66 | $-1.81 | $-1.54 | $-0.92 | $-0.82 | $-1.30 | $-1.33 | $-0.45 | $-0.76 |
| High Forecast | $-0.19 | $-0.24 | $-0.36 | $-0.44 | $-0.35 | $-0.72 | $-0.90 | $-1.00 | $-1.18 | $-0.90 | $-0.98 | $-1.11 | $0.52 | $-0.93 | $-1.41 | $-1.34 | $-1.38 | $-1.12 | $-1.37 | $-1.21 | $-1.35 | $-1.33 | $-1.46 | $-1.24 | $-0.74 | $-0.66 | $-1.04 | $-1.07 | $-0.36 | $-0.61 |
| Low Forecast | $-0.25 | $-0.32 | $-0.46 | $-0.57 | $-0.45 | $-0.94 | $-1.17 | $-1.30 | $-1.53 | $-2.06 | $-1.26 | $-1.44 | $-0.42 | $-1.20 | $-1.83 | $-1.73 | $-1.79 | $-1.45 | $-1.37 | $-1.85 | $-2.06 | $-2.04 | $-2.23 | $-1.90 | $-1.13 | $-1.01 | $-1.60 | $-1.63 | $-0.55 | $-0.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.02% | 1.65% | 0.00% | 1.23% | 1.48% | 1.19% | - | 1.18% | 1.21% | 1.14% | 0.93% | 1.18% | 1.20% | 1.25% | 2.14% | 1.36% | 3.06% | 1.40% |
According to undefined Wall Street analysts, PTC Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTCT previous annual EPS of $NaN (undefined).
PTC Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
PTCT Forecast FAQ
Is PTC Therapeutics a good buy?
No, according to 10 Wall Street analysts, PTC Therapeutics (PTCT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 30.00% of PTCT's total ratings.
What is PTCT's price target?
PTC Therapeutics (PTCT) average price target is $44.33 with a range of $32 to $63, implying a 30.42% from its last price of $33.99. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PTC Therapeutics stock go up soon?
According to Wall Street analysts' prediction for PTCT stock, the company can go up by 30.42% (from the last price of $33.99 to the average price target of $44.33), up by 85.35% based on the highest stock price target, and down by -5.85% based on the lowest stock price target.
Can PTC Therapeutics stock reach $50?
PTCT's highest twelve months analyst stock price target of $63 supports the claim that PTC Therapeutics can reach $50 in the near future.
What is PTC Therapeutics's current price target trend?
1 Wall Street analyst forecast a $47 price target for PTC Therapeutics (PTCT) this month, up 38.28% from its last price of $33.99. Compared to the last 3 and 12 months, the average price target increased by 16.21% and increased by 10.03%, respectively.
What are PTC Therapeutics's analysts' financial forecasts?
PTC Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $675.29M (high $741.29M, low $608.23M), average EBITDA is $-315M (high $-284M, low $-346M), average net income is $-262M (high $-229M, low $-296M), average SG&A $358.62M (high $393.68M, low $323.01M), and average EPS is $-3.421 (high $-2.979, low $-3.855). PTCT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.19B (high $1.3B, low $1.07B), average EBITDA is $-555M (high $-500M, low $-609M), average net income is $-109M (high $-94.544M, low $-122M), average SG&A $631.21M (high $692.91M, low $568.54M), and average EPS is $-1.415 (high $-1.232, low $-1.595).
Did the PTCT's actual financial results beat the analysts' financial forecasts?
Based on PTC Therapeutics's last annual report (Dec 2023), the company's revenue was $937.82M, beating the average analysts forecast of $932.7M by 0.55%. Apple's EBITDA was $-440M, beating the average prediction of $-407M by 8.01%. The company's net income was $-627M, beating the average estimation of $-331M by 89.20%. Apple's SG&A was $332.54M, missing the average forecast of $455.03M by -26.92%. Lastly, the company's EPS was $-0.0084, missing the average prediction of $-4.359 by -99.81%. In terms of the last quarterly report (Dec 2023), PTC Therapeutics's revenue was $307.06M, missing the average analysts' forecast of $314.96M by -2.51%. The company's EBITDA was $-335M, beating the average prediction of $-147M by 127.73%. PTC Therapeutics's net income was $-156M, beating the average estimation of $-10.604M by 1369.16%. The company's SG&A was $76.29M, missing the average forecast of $167.26M by -54.39%. Lastly, the company's EPS was $-0.0021, missing the average prediction of $-0.138 by -98.48%